Lv54
858 积分 2023-01-12 加入
Global, regional and national burden of primary liver cancer by subtype
2天前
已完结
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
8天前
已完结
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
8天前
已完结
Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
8天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
9天前
已完结
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
9天前
已完结
Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial
9天前
已完结
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
15天前
已完结
胆道恶性肿瘤围手术期治疗中国专家共识
17天前
已完结
胆道恶性肿瘤诊疗专家共识（2026版）
17天前
已完结
皖公网安备34019202002308
